The EBF1-PDGFRB T681I mutation is highly resistant to imatinib and dasatinib in vitro and detectable in clinical samples prior to treatment

Affiliations

• ¹ Division of Pediatric Hematology-Oncology, Charles-Bruneau Cancer Center, CHU Sainte-Justine, University of Montreal, Montreal, QC, Canada; Department of Pediatrics, Benioff Children's Hospital and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA. thai.hoa.tran@umontreal.ca.
• ² Department of Pediatrics, Benioff Children's Hospital and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA.
• ³ Department of Bioengineering and Therapeutic Sciences, Department of Pharmaceutical Chemistry, California Institute for Quantitative Biosciences, University of California, San Francisco, San Francisco, CA.
• ⁴ Wolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne.
• ⁵ Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN.
• ⁶ Division of Hematology-Oncology and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA.
• ⁷ Department of Biostatistics, College of Medicine and Public Health and Health Professions, University of Florida, Gainesville, FL.
• ⁸ Department of Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, TN.